RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.030
0.00 (0.00%)
At close: Feb 21, 2025, 4:00 PM
1.021
-0.009 (-0.90%)
After-hours: Feb 21, 2025, 4:39 PM EST
RenovoRx Employees
RenovoRx had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,145,375
Market Cap
24.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Dec 31, 2020 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
RNXT News
- 9 days ago - RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery - Business Wire
- 11 days ago - RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
- 16 days ago - RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock - Business Wire
- 16 days ago - RenovoRx Announces Proposed Public Offering - Business Wire
- 17 days ago - RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount - Seeking Alpha
- 26 days ago - RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 - Business Wire
- 6 weeks ago - RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 - Business Wire
- 7 weeks ago - RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform - Business Wire